DGAP-News: BLACKHAWK GROWTH'S MINDBIO THERAPEUTICS SUCESSFULLY PROGRESSED TO THE SECOND HALF OF THEIR PHASE 1 MICRODOSING CLINICAL TRIAL
Retrieved on:
Monday, October 4, 2021
Therapy, BLR, Sixth Labour Government of New Zealand, LSD, Black Hawk, Health, Intention, News, CSE, Patient, DGAP, New Zealand government response to the COVID-19 pandemic, Government, CEO, Acquisition, Company, SEDAR, Technology, Cannabis, Space food, Investment, Security (finance), Pharmaceutical industry
The progress in clinical trials makes MindBio a step closer towards commercialization and bringing new therapies to market.
Key Points:
- The progress in clinical trials makes MindBio a step closer towards commercialization and bringing new therapies to market.
- The clinical trials have been approved by the New Zealand Government who also contributed NZ$600,000 in funding to support this important safety study.
- Furthermore, the Government of New Zealand has provided an import license and approval for the substances to be administered at home.
- It is the first clinic trial of its kind in the world that tests microdosing of 80 participants with psychedelics in a community setting.